PT Diagnos Laboratorium Utama Tbk Statistics
PT Diagnos Laboratorium Utama Tbk (DGNS) Stock Statistics & Valuation Metrics
Total Valuation
PT Diagnos Laboratorium Utama Tbk has a market cap or net worth of IDR 398.75B. The enterprise value is IDR 469.87B.
- Market Cap
- IDR 398.75B
- Enterprise Value
- IDR 469.87B
Share Statistics
PT Diagnos Laboratorium Utama Tbk has 1,375,000,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,375,000,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
PT Diagnos Laboratorium Utama Tbk’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 0.93%.
- Return on Equity (ROE)
- 0.01
- Return on Assets (ROA)
- 0.01
- Return on Invested Capital (ROIC)
- 0.93%
- Return on Capital Employed (ROCE)
- 0.02
- Revenue Per Employee
- 2.06B
- Profits Per Employee
- 36.26M
- Employee Count
- 81
- Asset Turnover
- 0.52
- Inventory Turnover
- 15.63
Valuation Ratios
The current PE Ratio of PT Diagnos Laboratorium Utama Tbk is 153.76. PT Diagnos Laboratorium Utama Tbk’s PEG ratio is 0.89.
- PE Ratio
- 153.76
- PS Ratio
- 2.23
- PB Ratio
- 1.86
- Price to FCF
- 93.74
- Price to Operating Cash Flow
- 49.29
- PEG Ratio
- 0.89
Income Statement
In the last 12 months, PT Diagnos Laboratorium Utama Tbk had revenue of 166.62B and earned 2.94B in profits. Earnings per share was 2.35.
- Revenue
- 166.62B
- Gross Profit
- 71.61B
- Operating Income
- 5.08B
- Pretax Income
- 5.41B
- Net Income
- 2.94B
- EBITDA
- 16.40B
- Earnings Per Share (EPS)
- 2.35
Cash Flow
In the last 12 months, operating cash flow was 8.67B and capital expenditures -4.48B, giving a free cash flow of 4.20B billion.
- Operating Cash Flow
- 8.67B
- Free Cash Flow
- 4.20B
- Free Cash Flow per Share
- 2.81
Dividends & Yields
PT Diagnos Laboratorium Utama Tbk pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 1.07%
- Earnings Yield
- 0.48%
Stock Price Statistics
- Beta
- 0.77
- 52-Week Price Change
- 101.39%
- 50-Day Moving Average
- 277.08
- 200-Day Moving Average
- 264.97
- Relative Strength Index (RSI)
- 53.11
- Average Volume (3m)
- 2.08M
Important Dates
PT Diagnos Laboratorium Utama Tbk upcoming earnings date is Apr 06, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 31, 2026
- Next Earnings Date
- Apr 06, 2027
- Ex-Dividend Date
- ―
Financial Position
PT Diagnos Laboratorium Utama Tbk as a current ratio of 3.30, with Debt / Equity ratio of 38.85%
- Current Ratio
- 3.30
- Quick Ratio
- 3.08
- Debt to Market Cap
- 0.25
- Net Debt to EBITDA
- 4.32
- Interest Coverage Ratio
- 6.55
Taxes
In the past 12 months, PT Diagnos Laboratorium Utama Tbk has paid 2.47B in taxes.
- Income Tax
- 2.47B
- Effective Tax Rate
- 0.46
Enterprise Valuation
PT Diagnos Laboratorium Utama Tbk EV to EBITDA ratio is 27.82, with an EV/FCF ratio of 107.16.
- EV to Sales
- 2.55
- EV to EBITDA
- 27.82
- EV to Free Cash Flow
- 107.16
- EV to Operating Cash Flow
- 51.85
Balance Sheet
PT Diagnos Laboratorium Utama Tbk has IDR 18.20B in cash and marketable securities with IDR 73.06B in debt, giving a net cash position of -IDR 54.86B billion.
- Cash & Marketable Securities
- IDR 18.20B
- Total Debt
- IDR 73.06B
- Net Cash
- -IDR 54.86B
- Net Cash Per Share
- -IDR 39.90
- Tangible Book Value Per Share
- IDR 152.19
Margins
Gross margin is 45.53%, with operating margin of 3.42%, and net profit margin of 1.16%.
- Gross Margin
- 45.53%
- Operating Margin
- 3.42%
- Pretax Margin
- 2.56%
- Net Profit Margin
- 1.16%
- EBITDA Margin
- 9.16%
- EBIT Margin
- 3.25%
Analyst Forecast
The average price target for PT Diagnos Laboratorium Utama Tbk is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 14.41%
- EPS Growth Forecast
- ―
